IndiTreat
New data from 2cureX IndiTreat at ASCO
June's highly anticipated virtual ASCO conference will highlight new data from 2cureX clinical partner, Vejle...
2cureX unlocks the power of precision oncology
2cureX
2cureX a potential key player in precision cancer treatment
With the launch of IndiTreat last fall and the...
2cureX's IndiTreat achieves primary endpoint
After strengthening the management through the appointment of...
2cureX receives EU grant for its ovarian cancer project
Yesterday, on World Cancer Day, 2cureX announced that the company's newly...
2cureX has appointed a new CEO
2cureX announced today that Fernando Andreu has been appointed...
2020: the year of 2cureX's IndiTreat launch
Although it has been a challenging year...
Scandion Oncology tackles antiestrogen resistance
Scandion Oncology is currently evaluating its lead candidate...
Strong Q3 for 2cureX culminates in IndiTreat launch
Last week, 2cureX's Q3 report was released and it...
Patient recruitment completed in 2cureX clinical validation study
The official launch of 2cureX functional precision medicine test IndiTreat...
2cureX launches IndiTreat
The ESMO Conference 2020 provides a virtual platform to...
2cureX pre-launch activities pay off
We are approaching autumn and with it also 2cureX...